FOXL1 Antibody (monoclonal) (M03)
Mouse monoclonal antibody raised against a partial recombinant FOXL1.
- 产品详情
- 实验流程
Application ![]()
| WB |
---|---|
Primary Accession | Q12952 |
Other Accession | NM_005250 |
Reactivity | Human |
Host | mouse |
Clonality | monoclonal |
Isotype | IgG2b Kappa |
Clone Names | 1A7 |
Calculated MW | 36490 Da |
Gene ID | 2300 |
---|---|
Other Names | Forkhead box protein L1, Forkhead-related protein FKHL11, Forkhead-related transcription factor 7, FREAC-7, FOXL1, FKHL11, FREAC7 |
Target/Specificity | FOXL1 (NP_005241, 132 a.a. ~ 240 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | FOXL1 Antibody (monoclonal) (M03) is for research use only and not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
REFERENCES
Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. Kim MS, et al. J Pathol, 2010 Jun. PMID 20198651.Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Rivadeneira F, et al. Nat Genet, 2009 Nov. PMID 19801982.Candidate gene analysis in primary lymphedema. Ferrell RE, et al. Lymphat Res Biol, 2008. PMID 18564921.The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Gerhard DS, et al. Genome Res, 2004 Oct. PMID 15489334.Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry. Hassel S, et al. Proteomics, 2004 May. PMID 15188402.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.